198 related articles for article (PubMed ID: 18316563)
1. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
Morris M; Platell C; Iacopetta B
Clin Cancer Res; 2008 Mar; 14(5):1413-7. PubMed ID: 18316563
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
3. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
4. Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.
Morris M; Platell C; McCaul K; Millward M; van Hazel G; Bayliss E; Trotter J; Ransom D; Iacopetta B
Int J Colorectal Dis; 2007 Aug; 22(8):887-95. PubMed ID: 17235506
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Dregelies T; Norouzzadeh Z; Rund-Küffner S; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Aug; 36(8):1765-1779. PubMed ID: 33745027
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
Cha YJ; Park EJ; Baik SH; Lee KY; Kang J
Sci Rep; 2019 Aug; 9(1):11617. PubMed ID: 31406179
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
8. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
9. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.
Sinicrope FA; Shi Q; Smyrk TC; Goldberg RM; Cohen SJ; Gill S; Kahlenberg MS; Nair S; Shield AF; Jahagirdar BN; Jacobson SB; Foster NR; Pollak MN; Alberts SR
JNCI Cancer Spectr; 2021 Oct; 5(5):. PubMed ID: 34485815
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy and prognostic factors in stage II colon cancer--Izmir Oncology Group Study.
Kucukzeybek Y; Dirican A; Demir L; Yildirim S; Akyol M; Yildiz Y; Bayoglu IV; Alacacioglu A; Varol U; Salman T; Yildiz I; Can H; Tarhan MO
Asian Pac J Cancer Prev; 2015; 16(6):2413-8. PubMed ID: 25824774
[TBL] [Abstract][Full Text] [Related]
11. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
Saberzadeh-Ardestani B; Foster NR; Lee HE; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2022 Nov; 33(11):1159-1167. PubMed ID: 35963480
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
Yun HR; Kim HC; Yun SH; Lee WY
Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
[TBL] [Abstract][Full Text] [Related]
13. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Zhou ZG; Pan ZZ; Wan DS; Li LR; Wu XJ; Ding PR; Lin JZ; Peng ZH
Ai Zheng; 2009 Sep; 28(9):908-12. PubMed ID: 19728905
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
17. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
19. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis.
Powers BD; Felder SI; Imanirad I; Dessureault S; Dineen SP
J Gastrointest Cancer; 2021 Jun; 52(2):719-727. PubMed ID: 32743731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
